Atea Pharmaceuticals, Inc. (AVIR) Free cash flow 2019–2023
Atea Pharmaceuticals, Inc. (AVIR) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$87.3MFY2023 · since FY2019: -$12.8M → -$87.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -$87.3M | +27.8% |
| FY2022 | -$121.0M | -39.0% |
| FY2021 | -$87.0M | -129.3% |
| FY2020 | $296.7M | +2410.8% |
| FY2019 | -$12.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice